torcetrapib has been researched along with bosentan anhydrous in 1 studies
| Studies (torcetrapib) | Trials (torcetrapib) | Recent Studies (post-2010) (torcetrapib) | Studies (bosentan anhydrous) | Trials (bosentan anhydrous) | Recent Studies (post-2010) (bosentan anhydrous) |
|---|---|---|---|---|---|
| 273 | 28 | 83 | 1,836 | 215 | 630 |
| Protein | Taxonomy | torcetrapib (IC50) | bosentan anhydrous (IC50) |
|---|---|---|---|
| Endothelin receptor type B | Rattus norvegicus (Norway rat) | 0.095 | |
| Endothelin receptor type B | Homo sapiens (human) | 0.3044 | |
| Endothelin-1 receptor | Homo sapiens (human) | 0.2317 | |
| Endothelin-1 receptor | Rattus norvegicus (Norway rat) | 0.0047 | |
| Endothelin-1 receptor | Sus scrofa (pig) | 0.0075 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Besler, C; Bigler, L; Dörries, C; Hermann, M; Lüscher, TF; Ruschitzka, F; Shaw, SG; Simic, B; Stalder, U | 1 |
1 other study(ies) available for torcetrapib and bosentan anhydrous
| Article | Year |
|---|---|
Torcetrapib impairs endothelial function in hypertension.
Topics: Animals; Anticholesteremic Agents; Antihypertensive Agents; Aorta; Blood Pressure; Bosentan; Cells, Cultured; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Endothelin-1; Endothelium, Vascular; Hypertension; Immunohistochemistry; Intercellular Adhesion Molecule-1; Male; Muscle Contraction; Muscle, Smooth, Vascular; Nitric Oxide; Nitric Oxide Synthase Type III; Quinolines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Reactive Oxygen Species; Renin-Angiotensin System; Sulfonamides; Superoxides; Vascular Cell Adhesion Molecule-1 | 2012 |